# Compare KLOW, Wolverine, BPC-157 and TB-500 — Pro Peptide Strip

> A side-by-side comparison of four Recovery & Tissue Repair research peptides — KLOW, Wolverine, BPC-157 and TB-500 — across peptide class, evidence base, administration studied, regulatory and anti-doping status, and key caution.

Where the four repair entries converge, where they diverge, and how far the evidence behind each one actually reaches.

## The short version

This page lines up [KLOW](/klow), [Wolverine](/wolverine), [BPC-157](/bpc-157) and [TB-500](/tb-500) on the dimensions that matter most when reading research peptides: what kind of molecule or formulation each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, regulatory and anti-doping standing, and its single biggest caution.

The headline: all four are studied for recovery and tissue repair, but they are at very different evidence stages. KLOW and Wolverine are blends — no controlled combination study exists for either. BPC-157 has the deepest single-component animal record plus three small human pilots. TB-500's evidence largely belongs to the larger parent protein it fragments. None is an approved medicine. None is presented here with a human dose.

## The comparison matrix

| Dimension | KLOW | Wolverine | BPC-157 | TB-500 |
| --- | --- | --- | --- | --- |
| Peptide class | 4-component research blend (KPV 3aa + GHK-Cu 3aa + BPC-157 15aa + TB-500 7aa) | 2-component research blend (BPC-157 15aa + TB-500 7aa) | Stable gastric pentadecapeptide (15aa) | Synthetic actin-binding heptapeptide fragment of thymosin beta-4 (7aa) |
| Most-studied in | Component literature: gut, skin, tendon, wound (no blend study) | Component literature: angiogenesis + cell migration (no blend study) | Tendon, gut, muscle and nerve repair; angiogenesis | Actin biology; cell migration and wound healing (mostly full-length Tβ4) |
| Evidence base (model) | Individual components in rodents/cells; no controlled blend study [1] | Individual components in rodents/cells; no controlled blend study [8] | Mostly rat; 3 small human pilots [9] | Mostly full-length Tβ4 in animals; 1 human Phase 1 (full-length Tβ4) [1][15] |
| Administration studied | Components: IM, IP, topical, oral (no formal blend PK) | Components: IM, IV pilot, IP (no formal blend PK) [2][12] | IM, intragastric, drinking water, IV pilot [2][12] | IV (full-length Tβ4), IP in animals [14][15] |
| Regulatory / WADA | Not approved; WADA: TB-500/Tβ4 = S2 prohibited, BPC-157 = S0 prohibited [1] | Not approved; WADA: BPC-157 = S0 prohibited, TB-500/Tβ4 = S2 prohibited [1][8] | Not approved; WADA S0 prohibited [1] | Not approved; WADA-prohibited (peptide/growth-factor) [1] |
| Key caution | No blend study; untested combination; TB-500 WADA-prohibited; pro-angiogenic caution in cancer [1] | No combination study; TB-500 identity gap; preclinical-only human record [8][11] | Single-lab, preclinical-heavy; 3 tiny human pilots; very short half-life [9][12] | Fragment vs full-protein identity gap; non-monotonic dose-response; no fragment human trials [1][14] |

## Peptide class

The four span a structural range from blends to singles. KLOW is the most composite — a four-component co-formulation with masses ranging from a 3-amino-acid tripeptide (KPV, GHK-Cu) to a 15-amino-acid pentadecapeptide (BPC-157) and a 7-amino-acid acetylated fragment (TB-500). Wolverine is the two-component subset of KLOW, pairing just BPC-157 and TB-500. BPC-157 is the largest individual peptide at 15 amino acids, a stable gastric pentadecapeptide. TB-500 is the smallest at 7 amino acids — but it is a fragment, and the majority of its cited evidence comes from the much larger (~4963 Da) full-length thymosin beta-4 [11].

## Most-studied in

Each entry has a home territory reflecting its proposed mechanisms. KLOW as a blend has no dedicated study territory — its research record is borrowed entirely from four individual components: gut and immune tissue (KPV), skin and matrix (GHK-Cu), tendon and vascular tissue (BPC-157), and cytoskeletal dynamics (TB-500/Tβ4). Wolverine inherits the same BPC-157 and TB-500 literature. BPC-157 as a single compound has the broadest animal record — tendon, gut, muscle, nerve — unified by angiogenesis [10]. TB-500 / thymosin beta-4 research centers on actin biology and the cell migration, angiogenesis and wound healing that follow from it [11].

## Evidence base (model)

This is where the four genuinely separate. KLOW and Wolverine share the same baseline: component data only, no controlled blend study [1][8]. BPC-157 has the deepest individual animal record — three decades, multiple tissue types — plus three small uncontrolled human pilots; a 2025 narrative review explicitly states only three such pilots exist and recommends treating it as investigational [9]. TB-500 is the most nuanced: a Phase 1 IV safety study in 40 volunteers used full-length thymosin beta-4, not the marketed 7-mer fragment [15]; the fragment itself has no completed controlled human trials [1]. Across all four, the honest summary is: animal-model promise, scarce human data, and no combination evidence.

## Administration studied

Administration routes track the research questions. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot; its very short elimination half-life (under 30 minutes) is established by formal PK/ADME work in rats and dogs [2][12]. TB-500 / full-length Tβ4 was dosed intravenously in the human Phase 1 study and intraperitoneally in the rat stroke dose-response [14][15]. For KLOW and Wolverine, administration routes are those of their individual components — no formal blend pharmacokinetic study exists for either formulation [1][8].

## Regulatory / WADA status

None of the four is an FDA- or EMA-approved medicine for systemic human use. Both blends carry WADA implications: KLOW contains TB-500 (S2, peptide hormones/growth factors, prohibited at all times) and BPC-157 (S0, non-approved substances, prohibited at all times); Wolverine contains both of those same two [1][8]. BPC-157 standalone is WADA S0 prohibited [1]. TB-500 standalone is prohibited under peptide/growth-factor categories and has been detected as a doping agent in racehorses [1]. For any individual subject to anti-doping rules, all four entries on this desk are off-limits.

## Key caution

Each entry has a defining constraint. For KLOW it is the absence of any blend study combined with an inherent pharmacokinetic mismatch — the tripeptides clear far faster than BPC-157, which itself clears in under 30 minutes — meaning a co-formulated vial cannot deliver matched exposures [1][12]. For Wolverine it is the TB-500 identity gap: the marketed fragment is not the molecule behind most of the Tβ4 efficacy literature [8][11]. For BPC-157 it is the single-lab concentration of the foundational preclinical literature, with only three tiny human pilots and no long-term safety data [9]. For TB-500 it is the combination of the fragment identity gap and a non-monotonic dose-response in animals — where a higher dose produced less benefit than a lower one [14]. Reading all four together, the message is consistent: mechanistically plausible signals, early and mostly preclinical evidence, and no controlled human combination data at all.

---

A clinical literature briefing on research peptides — peer-reviewed citations, no products, no prescriptions.